Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 safety and tolerability study of macitentan in patients with idiopathic pulmonary fibrosis was withdrawn. No results or ongoing enro…
-
CLINICAL_TRIALS withdrawal · 2025-04-09Clinical Trial Update: A Study to Investigate Leramistat in Patients With IPF [Phase 2]
A Phase 2 clinical trial evaluating Leramistat for idiopathic pulmonary fibrosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-05-01Clinical Trial Update: Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil [Phase 4]
Phase 4 trial evaluating sildenafil for pulmonary hypertension associated with idiopathic pulmonary fibrosis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-03-06Clinical Trial Update: Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan [Phase 4]
A Phase 4 study investigating bosentan for pulmonary arterial hypertension secondary to idiopathic pulmonary fibrosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-28Clinical Trial Update: Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
The IPF registry trial NCT00212511 sponsored by NYU Langone Health has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
A Phase 2 clinical trial evaluating oral vismodegib for idiopathic pulmonary fibrosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-01-05Clinical Trial Update: A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations [Phase 2]
A Phase 2 trial evaluating plasmapheresis, rituximab, and steroids for acute idiopathic pulmonary fibrosis exacerbations has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-11-30Clinical Trial Update: Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis
The clinical trial NCT02187393, sponsored by the University of Colorado, Denver, investigating epithelial cell properties in individuals wit…